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CONSENSUS RECOMMENDATIONS

Hypoactive Sexual Desire Disorder: International
Society for the Study of Women’s Sexual Health
(ISSWSH) Expert Consensus Panel Review
Irwin Goldstein, MD; Noel N. Kim, PhD; Anita H. Clayton, MD;
Leonard R. DeRogatis, PhD; Annamaria Giraldi, MD, PhD; Sharon J. Parish, MD;
James Pfaus, PhD; James A. Simon, MD; Sheryl A. Kingsberg, PhD;
Cindy Meston, PhD; Stephen M. Stahl, MD; Kim Wallen, PhD;
and Roisin Worsley, MBBS
Abstract
The objective of the International Society for the Study of Women’s Sexual Health expert consensus panel
was to develop a concise, clinically relevant, evidence-based review of the epidemiology, physiology,
pathogenesis, diagnosis, and treatment of hypoactive sexual desire disorder (HSDD), a sexual dysfunction
affecting approximately 10% of adult women. Etiologic factors include conditions or drugs that decrease
brain dopamine, melanocortin, oxytocin, and norepinephrine levels and augment brain serotonin,
endocannabinoid, prolactin, and opioid levels. Symptoms include lack or loss of motivation to participate
in sexual activity due to absent or decreased spontaneous desire, sexual desire in response to erotic cues or
stimulation, or ability to maintain desire or interest through sexual activity for at least 6 months, with
accompanying distress. Treatment follows a biopsychosocial model and is guided by history and assessment of symptoms. Sex therapy has been the standard treatment, although there is a paucity of studies
assessing efﬁcacy, except for mindfulness-based cognitive behavior therapy. Bupropion and buspirone
may be considered off-label treatments for HSDD, despite limited safety and efﬁcacy data. Menopausal
women with HSDD may beneﬁt from off-label testosterone treatment, as evidenced by multiple clinical
trials reporting some efﬁcacy and short-term safety. Currently, ﬂibanserin is the only Food and Drug
Administrationeapproved medication to treat premenopausal women with generalized acquired HSDD.
Based on existing data, we hypothesize that all these therapies alter central inhibitory and excitatory
pathways. In conclusion, HSDD signiﬁcantly affects quality of life in women and can effectively be
managed by health care providers with appropriate assessments and individualized treatments.
ª 2016 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/) n Mayo Clin Proc. 2017;92(1):114-128
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ypoactive sexual desire disorder
(HSDD), the most prevalent female
sexual health problem,1 was considered the persistent or recurrent deﬁciency or
absence of sexual fantasies and desire for sexual activity with marked distress or interpersonal difﬁculty not otherwise accounted for
by a general medical or psychiatric condition.
An HSDD may be primary or secondary, lifelong or acquired, or generalized or situational.
The broadened deﬁnition of HSDD may
include any of the following: (1) lack of motivation for sexual activity as manifested by
either reduced or absent spontaneous desire
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(sexual thoughts or fantasies) or reduced or
absent responsive desire to erotic cues and
stimulation or inability to maintain desire or
interest through sexual activity or (2) loss of
desire to initiate or participate in sexual activity, including behavioral responses such as
avoidance of situations that could lead to sexual activity, that is, not secondary to sexual
pain disorders, and is combined with clinically
signiﬁcant personal distress that includes frustration, grief, incompetence, loss, sadness,
sorrow, or worry.2
Women with HSDD have been found to
have impaired body image, self-conﬁdence,
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under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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and self-worth and to feel less connected to
their partners.3 Total health care expenditures
compared with a control patient cohort were
higher for women with HSDD, including
outpatient ofﬁce visits, prescription medication use, and other medical services, including
radiology, laboratory, and outpatient procedures.4 Comorbidities include depression and
fatigue, similar to chronic conditions such as
diabetes and back pain.4,5 Research on the
neuroendocrine central mechanisms of sexual
desire has led to an improved understanding
of the underlying pathogenesis of this
biopsychosocial condition. Misunderstandings
about HSDD exist, leaving few clinicians
feeling competent to inquire about or treat
this condition.
Despite the existence of numerous publications on HSDD, what has been lacking is a
concise resource that assists the clinician (internists/primary care physicians, gynecologists, urologists, and advanced practice
providers) in competently screening the
female patient for HSDD and providing appropriate therapeutic options in a biopsychosocial
paradigm. To this end, the International Society for the Study of Women’s Sexual Health
(ISSWSH) commissioned a panel of experts
to write a concise review of the state-of-theart understanding of the neural circuitry that
regulates sexual desire, including a plausible
explanation for persistent states of both
normal and hypoactive sexual desire; a
description of current on- and off-label treatment strategies, including their beneﬁts and
pitfalls; and a discussion of the rationale for
using various therapies.
METHODS
In January 2016, the ISSWSH executive
committee chose co-chairs for this project to
identify potential panelists based on individuals’ publications and research. After a planning conference call with the chosen experts,
panelists were asked to individually perform
an evidence-based literature review in their
respective topics, identifying high-quality
publications that they judged to be important
and pertinent to the topic. Literature selection
criteria were not systematically deﬁned but
were based on the expertise and experience
of each panelist. The panel of 13 researchers
Mayo Clin Proc. n January 2017;92(1):114-128
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and clinicians convened in Dallas, Texas, to
present and discuss the current state of knowledge of HSDD. Participants declared potential
conﬂicts of interest and were ISSWSH members and nonmembers. Panelists deliberated
on the history, pathogenesis, diagnostic
process, and treatment of HSDD and were
assigned to writing groups for the development of this article.
The ISSWSH is a not-for-proﬁt multidisciplinary academic and scientiﬁc organization
dedicated to supporting the highest standards
of ethics and professionalism in the research,
education, and clinical practice of women’s
sexual health. The ISSWSH received an unrestricted grant from industry for the development of this document. No industry
representatives were present in the closed committee meetings; there was no industry participation in the evidence selection, discussion, or
creation of this document; and there was no
attempt by industry to inﬂuence its content.
History of HSDD and Nosology
Historically, the diagnoses of female sexual
dysfunctions have been made principally by
clinical presentation and patient history
rather than by nosology based on etiology,
pathogenesis, and clinical phenomenology.
Development of the diagnostic concept of
HSDD is closely tied to the evolution of the
Diagnostic and Statistical Manual of Mental
Disorders (DSM) system, the diagnostic classiﬁcation system of the American Psychiatric
Association.6 The diagnostic category of
HSDD has existed for approximately 30 years,
with its antecedents labeled differently but
deﬁned in a similar manner.7-11 The deﬁnition
has evolved with the text-revised versions of
the DSM-IV and the DSM-5.10,11 In the
DSM-5, HSDD has been eliminated as a
distinct nosologic entity and has been replaced
with an amalgamation of the DSM-IV HSDD
and female sexual arousal disorder diagnoses,
termed female sexual interest/arousal disorder.
This revised classiﬁcation has been controversial among experts in the area of sexual medicine because there is little empirical support
or validation of the new diagnostic category/
criteria in contemporary clinical research.12,13
Concern over what some consider to be
the inappropriate elimination of the diagnostic
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category of HSDD in DSM-5 has resulted in
the development of an autonomous nosology
for female sexual dysfunctions by two international panels of experts in sexual medicine (the
ISSWSH Nomenclature Committee and the
International Consultation in Sexual Medicine).2,14 Importantly, the ISSWSH nosology
retains HSDD as a distinct diagnostic entity,
consistent with what many believe to be
empirically based clinical experience. This
classiﬁcation system is also consistent with
the International Statistical Classiﬁcation of
Diseases and Related Health Problems, 10th Revision (ICD-10) nomenclature system,15 which is
used throughout the world and applies to both
the somatic and psychiatric diagnostic
systems. In the ICD-10, HSDD (ICD-10 code
F 52.0) is represented as an independent diagnostic category, as it had been in the DSM
system before DSM-5.
Epidemiology
Hypoactive sexual desire disorder is a common but frequently undiagnosed condition.
Initially, epidemiologic studies examining the
prevalence of low desire in women did not
take into account the associated bother and
distress, a cardinal symptom of HSDD. However, they did associate lower quality-of-life
measures (eg, physical and emotional satisfaction with sexual partners and general happiness) in women with low desire compared
with women with no sexual problems.16 In
later studies that examined low sexual desire
with distress in large cohorts of premenopausal and postmenopausal women in the
general population, the overall prevalence of
HSDD ranged from approximately 8% to
19%.1,17-19 These studies also found associations between distressing low sexual desire
and lower health-related quality of life, as
well as psychosocial factors such as dissatisfaction with sex life, partner, or marriage and
negative emotional states, including frustration, hopelessness, anger, poor self-esteem,
and loss of femininity.
When subgroups were further characterized, women with a current spouse or partner were more likely to experience
concomitant distress with low sexual desire
than nonpartnered women.20 In addition,
self-assessed poor health, thyroid disease,
and urinary incontinence were associated
116
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with increased probability of distressing low
sexual desire. There was also a marked association between depression and anxiety and
distressing low sexual desire.21 Interestingly,
although the prevalence of low sexual desire
increased with age and was higher in naturally menopausal women, the prevalence of
associated distress declined with increasing
age.17 Similarly, in a study of US and European women aged 20 to 70 years, the occurrence of low desire increased with age and
distress about low desire decreased, resulting
in relatively constant prevalence rates
of distressing low sexual desire with age
(12%-19% in the United States and
6%-13% in Europe).18
One potential limitation of populationbased surveys is that the data are selfreported, with no independent veriﬁcation.
Thus, it is important that a multicenter, longitudinal, observational study of women with
clinically diagnosed HSDD was initiated in
2008 and completed enrollment of 1592
participants into an HSDD registry.22 Among
the baseline ﬁndings, one-third of the 1088
premenopausal women had symptoms or a
clinical diagnosis of depression.23 In a
subgroup of 426 premenopausal women
and 174 postmenopausal women with
HSDD, a signiﬁcant proportion (54% premenopausal; 66% postmenopausal) had
concomitant arousal or lubrication problems.24 These data illustrate the importance
of accurately and completely assessing patients presenting with HSDD to detect any
possible concomitant conditions and optimize treatment.
Physiologic Mechanisms Modulating Sexual
Desire
Sexual desire has been studied in both the
clinical and laboratory settings. Validated
patient-reported instruments (eg, the Female
Sexual Function Index) enable clinically sensitive assessment of changes in sexual desire. In
animal studies, sexual desire can be reliably
inferred from behaviors that anticipate or solicit sexual interaction or otherwise indicate
sexual interest. These behaviors and underlying cognitive, emotional, and regulatory processes are controlled by brain systems
involved in sexual excitation and inhibition.25-30

January 2017;92(1):114-128

n

http://dx.doi.org/10.1016/j.mayocp.2016.09.018
www.mayoclinicproceedings.org

HYPOACTIVE SEXUAL DESIRE DISORDER: ISSWSH REVIEW

Limbic integrator
DA
Serotonin
NE
μ,δ
MSH
CB1s
GnRH
OT

Appetitive responses
CPu

ACC
VP

NAcc

Excitatory
Inhibitory

ArcN

Pir Ctx

mPOA
VTA
Tu

PFC
Sexual pleasure
PIT
Regulation/
reward

Conscious
awareness/evaluation

FIGURE 1. Neural pathways regulating sexual desire in the brain. The main excitatory (solid green) and
inhibitory (dashed red) pathways between key brain regions are depicted. Black pathways represent
known connections that can be both excitatory and inhibitory. Neurotransmitters (see icon key) and their
approximate sites of action are shown. Each neurotransmitter is highlighted to denote the excitatory
(green) or inhibitory (red) effect on speciﬁc pathways or at speciﬁc sites. The number of icons indicates
the relative strength of inﬂuence of a given neurotransmitter. The Venn diagram overlay represents 3
interactive functional systems that process external stimuli through evaluation of sexual reward that may
be integrated to facilitate or attenuate appetitive responses characteristic of sexual desire. ACC ¼ anterior
cingulate cortex; ArcN ¼ arcuate nucleus of the hypothalamus; CB1s ¼ cannabinoid type 1 receptor;
CPu ¼ caudate-putamen; d ¼ delta opioid receptors; DA ¼ dopamine; GnRH ¼ gonadotropin-releasing
hormone; m ¼ mu opioid receptors; mPOA ¼ medial preoptic area; MSH ¼ melanocyte-stimulating
hormone; NAcc ¼ nucleus accumbens; NE ¼ norepinephrine; OT ¼ oxytocin; PFC ¼ prefrontal
corex; Pir Ctx ¼ piriform cortex; PIT ¼ pituitary; Tu ¼ olfactory tubercle; VP ¼ ventral pallidum; VTA ¼
ventral tegmental area. Adapted from Encyclopedia of Behavioral Neuroscience.29

Neural Regulation. Key regions in the
brain that regulate sexual desire include
the prefrontal cortex, locus coeruleus, medial
preoptic area, paraventricular nucleus, and
reward- and attention-processing centers of
the ventral tegmental area and the nucleus
accumbens (Figure 1).25-30 Sexual excitation
involves the actions of brain dopamine, melanocortin, oxytocin, vasopressin, and norepinephrine. These neurotransmitters coordinate
pathways in the hypothalamus, limbic system,
and cortex to process and respond to sexual
stimuli. Sexual inhibition involves brain
Mayo Clin Proc. n January 2017;92(1):114-128
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opioid, serotonin, and endocannabinoid systems that are activated normally during sexual
refractoriness or as a function of primary
aversion or secondary avoidance. These
inhibitory systems blunt the ability of excitatory systems to be activated.
A large aggregate of animal and human
literature on the psychopharmacology of sexual motivation and desire28-30 reports that sexual desire can be inhibited by drugs or
conditions that (1) decrease brain dopamine
levels, (2) augment the action of brain serotonin speciﬁcally through serotonin 2A

http://dx.doi.org/10.1016/j.mayocp.2016.09.018
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receptors, or (3) increase opioids acting at mu
receptors. Conversely, sexual desire can be
stimulated by drugs or conditions that (1) increase hypothalamic and mesolimbic dopamine or (2) decrease serotonin release or
inhibit postsynaptic binding in the prefrontal
cortex. Drugs that can selectively activate these
stimulatory pathways or reduce inhibitory
pathways are being actively evaluated for the
treatment of HSDD, with one (ﬂibanserin)
currently approved by the Food and Drug
Administration (FDA).
Hormonal Regulation. Sexual motivation and
desire peaks in women and nonhuman
mammalian females during the periovulatory
period.31-34 This peak is driven by ovarian
hormone actions that prime excitatory sexual
systems in the brain and periphery.35 However,
during much of the 20th century it was generally believed that women’s sexual desire was not
inﬂuenced by ovarian hormones.36 Although
earlier equivocal studies suggested that adrenal
androgens were crucial to women’s sexual
desire,37 evidence that ovariectomy reduced or
eliminated women’s sexual desire was not
published until the 1980s.38-40 Because these
ovariectomized women had functioning adrenal cortices, these ﬁndings ruled out the notion
that adrenal androgens were critical to women’s
sexual desire. Thus, the focus shifted to ovarian
corticosteroids, including estradiol and testosterone, as modulators of women’s sexual desire.
Although there remain problematic aspects
with the accuracy of testosterone assays for
women and in interpreting different experimental designs, hormone therapy studies
found that testosterone increased sexual desire
in surgically and naturally postmenopausal
women, as well as in premenopausal
women.41,42 In these studies, total testosterone
plasma levels were in the upper normal or
supraphysiologic range, although this does
not necessarily predict levels of bioavailable
and free testosterone.36 In contrast, in a study
of naturally menopausal women, the decline
in sexual desire was best predicted by declines
in estradiol rather than testosterone.43 In
premenopausal women, studies of changes in
sexual desire in relation to changes in ovarian
hormone levels across the menstrual cycle
have produced mixed results, potentially due
to differences in methods, including using
118
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frequency of sexual intercourse as a proxy
for sexual desire and the interval of ovarian
hormone measurements.36,44 Nevertheless,
when sexual desire and ovarian hormone
levels were measured daily, estradiol was positively correlated with sexual desire, progesterone was associated with decreased sexual
desire, and testosterone levels did not predict
any aspect of women’s sexual desire.43
Yet, recent clinical consensus statements
do not support the use of estrogen as a therapeutic intervention to treat HSDD.45 In addition, ovarian testosterone levels show a
short-term rise during ovulation. It is possible
that this rise could activate excitatory sexual
mechanisms directly through androgenic
action or indirectly either through conversion
to estrogen by aromatase. Alternatively, the
secreted androgen may bind to corticosteroid
hormone-binding globulins in blood, thus
allowing more estradiol to get into the brain,
where it stimulates excitatory sexual mechanisms. Thus, hormones are important regulators of sexual desire but are among a myriad
of other factors that are integrated in the excitatory and inhibitory pathways in the brain.
Pathogenesis of HSDD. The precise biological alterations that cause HSDD remain
incompletely characterized. Clinically, no
identiﬁable hormonal differences characterize
premenopausal women with HSDD. Postmenopausal women often experience lower levels
of sexual desire but have lower rates of
distress.46 Although lower testosterone levels
have been associated with decreased sexual
desire, there is no level of testosterone that
predicts HSDD.47 Similarly, low sexual desire
is also associated with decreased estradiol
levels, but women with HSDD do not necessarily have low estradiol levels. Thus, although
ovarian corticosteroids may modulate
women’s sexual desire, their exact role in
HSDD remains unclear.
Irrespective of whether imbalances in
hormone levels play a causative role, it is likely
that primary and secondary generalized HSDD
involves either a predisposition toward inhibitory pathways in the brain48 or functional and
structural neuroadaptations in these systems
that result in decreased excitation, increased
inhibition, or some mix of the two. Such
dynamic alterations in brain function and
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structure may be additionally modulated or
reinforced by experience and behavior, further
propagating the condition. This process of
experience-based neuroplasticity is not unique
to HSDD and links behavior to cellular mechanisms (neuronal circuits), synaptic mechanisms
(long-term potentiation or inhibition of synaptic strength), and molecular mechanisms (ion
channels, cell surface receptors, transcriptional
and translational events, and epigenetic modiﬁcations).49,50 This proposed mechanism is also
consistent with differential brain activity
patterns and structural differences between
women with and without HSDD.51-54
Among the most dramatic differences,
positron emission tomography studies of volunteers shown erotic videos indicate that
women with HSDD have weaker activation
of the cerebral cortex in the right hemisphere
and signiﬁcantly less deactivation in the left
hemisphere compared with women who do
not have HSDD (Figure 2A). It is possible
that the weaker activation of the right side
may represent a muted response to sexual
cues, whereas the inability to deactivate
higher-order analytical processing on the left
side may perpetuate inhibitory neural pathways.
Mechanistically,
experience-based
neuroplasticity may explain how multiple
modalities of psychological and medical treatment can beneﬁt a patient with HSDD by
potentially modulating the underlying sexual
inhibition and excitation mechanisms in the
brain (Figure 2B).
Diagnosis of HSDD
The diagnosis of HSDD begins with a thorough history to determine whether the root
cause is neurobiological, interpersonal,
psychosocial, or some combination of these.
The diagnosis of HSDD may include bothersome/distressing symptoms of reduced motivation for participation in sexual activity due
to decreased spontaneous desire (sexual
thoughts/cognitions or fantasies), sexual desire
in response to erotic cues and stimulation, or
ability to maintain desire or interest through
sexual activity. Symptoms may also include
distressing behavioral manifestations of amotivation, such as (1) reduced or absent initiation
of sexual activity, (2) avoidance of situations
that could lead to sexual activity (eg, going
to bed after partner is asleep, restricting casual
Mayo Clin Proc. n January 2017;92(1):114-128
www.mayoclinicproceedings.org
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physical contact so as not to lead the partner
to misperceive an interest in sex, etc), and
(3) participation in sexual activity only out of
obligation or fear of loss of partner. Relationship issues may lead to low desire but should
be addressed and excluded as the primary etiology before diagnosing generalized acquired
HSDD. The diagnosis of HSDD does not
require complete loss of sexual desire but
rather a change for at least 3 months from
what it was previously. Importantly, personal
distress is a prerequisite for the diagnosis of
HSDD. The distress may manifest as frustration, grief, incompetence, loss, sadness, sorrow, low self-esteem, confusion, or worry,
but these should not be the cause of the
diminished desire.10,14
History/Screening. Health care providers
should initiate the general discussion and
assessment of sexual concerns because patients are often uncomfortable and unwilling
to bring up the topic. Initial screening tools
can facilitate the discussion of HSDD. The
Decreased Sexual Desire Screener (Table 1),
a 5-question instrument completed by the
patient, was developed and validated for use
by clinicians to aid in making the diagnosis of
HSDD in premenopausal and postmenopausal women per the DSM-IV-TR and
ISSWSH criteria.2,56,57 Women indicate yes/
no responses to the 5 questions (Table 1). The
purpose of questions 1 through 4 is to
determine whether there is HSDD. If the
patient responds yes to all the questions, this
is consistent with generalized acquired
HSDD.
The purpose of question 5 is to help determine whether the etiology of HSDD is primary
or secondary. In the case of secondary HSDD,
it is important to treat the underlying cause.
The presence of psychiatric and medical conditions, other sexual issues in the woman or
her partner, use of substances/medications,
or relationship problems as a cause of the
diminished desire would be consistent with a
diagnosis of secondary HSDD. Discrepancy
of the level of desire between a woman and
her partner does not qualify the person with
the lower desire as having HSDD per se.
Note that having regular sex with a partner
does not necessarily indicate that a woman
does not have HSDD given that women have

http://dx.doi.org/10.1016/j.mayocp.2016.09.018
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Treatment
Psychological
therapy
(mindfulness,
sensate
focus, CBT)

Hypothetical mechanisms of action

PFC
Trophic (neuroplastic)
and functional effects

Experience/
behavior
NAcc
Testosterone

Androgenic action

mPOA

Serotonin 2A
receptor antagonist

Decreased activation of PFC,
increased activation of
mPOA, VTA, and NAcc

Flibanserin
Serotonin 1A
receptor partial agonist

VTA

Decreased
serotonin

Buspirone

Increased
NE and DA

Presynaptic DA
receptor antagonist

Bupropion

Reuptake inhibitor for
NE and DA

B
FIGURE 2. A, Changes in neural activity in response to viewing an erotic video in women with or without
hypoactive sexual desire disorder (HSDD) assessed by positron emission tomography. Decreased activation, observed primarily in the left hemisphere, is shown in red, and increased activation, observed
primarily in the right hemisphere, is shown in green. Minimal deactivation was observed in the right
hemisphere and minimal activation was observed in the left hemisphere. Adapted with permission from
Sex Med Rev.55 B, Current treatments for HSDD and their hypothetical mechanisms of action. All
treatment modalities are hypothesized to modify the functional neural pathways summarized in Figure 1
through experiential stimuli, corticosteroid hormone action, and/or modulation of neurotransmitter
levels. CBT ¼ cognitive behavior therapy; DA ¼ dopamine agonist; mPOA ¼ medial preoptic area;
NAcc ¼ nucleus accumbens; NE ¼ norepinephrine; PFC ¼ prefrontal cortex; VTA ¼ ventral tegmental
area.
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TABLE 1. Decreased Sexual Desire Screener
1.
2.
3.
4.
5.

d

d

d

In the past, was your level of sexual desire or interest good and satisfying to you?
O Yes
O No
Has there been a decrease in your level of sexual desire or interest?
O Yes
O No
Are you bothered by your decreased level of sexual desire or interest?
O Yes
O No
Would you like your level of sexual desire or interest to increase?
O Yes
O No
Please check all the factors that you feel may be contributing to your current
decrease in sexual desire or interest:
a. An operation, depression, injuries, or other medical conditions
O Yes
O No
b. Medications, drugs, or alcohol you are currently taking
O Yes
O No
c. Pregnancy, recent childbirth, menopausal symptoms
O Yes
O No
d. Other sexual issues you may be having (pain, decreased arousal, or orgasms)
O Yes
O No
e. Your partner’s sexual problems
O Yes
O No
f. Dissatisfaction with your relationship or partner
O Yes
O No
g. Stress or fatigue
O Yes
O No
If the patient answers no to any of the questions 1-4, then she does not qualify for the diagnosis of generalized
acquired hypoactive sexual desire disorder (HSDD).
If the patient answers yes to all of the questions 1-4, and your review conﬁrms no answers to all of the factors in
question 5, then she does qualify for the diagnosis of generalized acquired HSDD.
If the patient answers “yes” to all of the questions 1-4 and “yes” to any of the factors in question 5, then decide
whether the answers to question 5 indicate a primary diagnosis other than generalized acquired HSDD. Comorbid
conditions such as arousal or orgasmic disorder do not rule out a concurrent diagnosis of HSDD.

Reprinted with permission from J Sex Med.56

sex for many reasons unrelated to sexual
desire (eg, sexual coercion or out of fear or
duty).58
Obtaining a detailed description of the
woman’s problem, including the onset, duration, and severity of her low sexual desire
symptoms and her level of distress and bother,
may further establish the diagnosis and guide
treatment. Overlap of female sexual disorders
is common, such as HSDD impairing arousal
that impairs orgasm or may lead to pain (eg,
attempting penetration without adequate
lubrication because she is not interested or
aroused). A full sexual history can help delineate the primary problem, establish diagnoses,

and assist in developing an approach to individualize treatment.
Additional Evaluation/Testing. Although a
physical examination is not required to make
the diagnosis of HSDD, it may be appropriate,
based on history, to rule out other factors that
may be contributing to the low sexual interest
condition, such as concerns of pain with
sexual activity or ﬁndings consistent with
hormone insufﬁciency states.
Although laboratory testing is not used to
make a diagnosis of HSDD, thyroid hormone
and prolactin levels should be measured where
clinically indicated to exclude an endocrine

TABLE 2. Example of Using the PLISSIT Model
(P) Permission: the provider explicitly encourages a woman to discuss any sexual concerns or questions she may
have and validates her right to satisfying sexual function.
Y
d (LI) Limited Information: the practitioner may educate the patient about sexual physiology or suggest educational
resources such as literature, videos, and erotica.
Y
d (SS) Speciﬁc Suggestions: the clinician provides tailored approaches designed to improve sexual and emotional
communication, such as sensate focus exercises, masturbation, Kegel exercises, technical advice regarding sexual
positions, and the use of lubricants or dilators.
Y
d (IT) Intensive Therapy: may involve referral for individual or couples therapy to deal with long-standing conﬂict
that is contributing to a woman’s hypoactive sexual desire.
d

Mayo Clin Proc. n January 2017;92(1):114-128
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problem that may be causing or contributing to
low desire. Testosterone and sex hormonebinding globulin levels are also not required
for the diagnosis of HSDD but are recommended if considering testosterone therapy.
Referral for assessment by a psychotherapist
is indicated if psychological or interpersonal/
relationship problems seem to be etiologically
related to the low desire or as a component of
a multimodal treatment approach regardless of
etiology. Referral for psychotherapy assessment
should not limit or postpone further medical
evaluation of HSDD if indicated.
Treatment of HSDD
The treatment of HSDD may engage both
psychosocial and biological strategies because
psychosocial/interpersonal and biological
factors impact each other.59 However, it is
reasonable to sequence treatment that focuses
on the suspected primary contributing component(s), emphasizing treatment of the factors
that are most distressing to that individual
woman. Brief ofﬁce-based counseling may be
helpful using the PLISSIT model (Permission,
Limited Information, Speciﬁc Suggestions,
and Intensive Therapy), a stepped approach
speciﬁcally for general health care providers
caring for women with sexual concerns
(Table 2).60 If psychotherapy is indicated,
the patient should be referred to a sex therapist for management, including determination
of the appropriate form of therapy for that
patient or couple.
Cognitive and Motivational Aspects. Psychotherapy is a recognized treatment strategy for
HSDD, typically focused on modifying
thoughts, beliefs, behaviors, emotions, and relationship communication/behaviors that interfere with desire. Cognitions typically addressed
include negative thoughts, beliefs, expectations,
cultural and religious standards, and attributions about sex, sexual activity, and altering/
correcting other thoughts that inhibit sexual
desire/lack of desire. Reactive sexual behaviors
(or avoidance) maintain negative cognitions/
emotional reactions, contributing to loss of
desire. With modiﬁcation of these behaviors to
elicit positive emotional reactions and with positive reinforcement, the behaviors are more
likely to be repeated and continued. Emotions
refer to negative and positive feelings, such as
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conﬁdence, body image, and resentments. Relationship dimensions are (1) identiﬁcation of
aspects such as couple expectations, autonomy,
cohesion, and commitment; (2) cooperation,
including interactions, conﬂict handling, and
pressure from partner; (3) emotional intimacy,
such as relationship feelings, empathy, and pressure; and (4) determination regarding whether
the relationship conﬂict is the source of loss of
desire or whether loss of desire led to relationship conﬂict.59 A woman with a desire
discrepancy (less desire than her partner) may
feel pressured and consequently perceive sex as
a chore or, worse, aversive. The treatment
focuses on the dynamic interplay between the
woman and her partner in their sexual relationship. Questions during the assessment may
focus on how the woman/couple function
cognitively, their sexual behavior and skills,
communication of sexual needs, and sufﬁciency
of sexual stimulation.
Sensate focus. Sensate focus therapy involves
a graded series of nondemand sensual
touching exercises.61 Typically used with
couples, the objectives of sensate focus therapy are to reduce anxiety and avoidance of
sensual touching or sexual activity, improve
sexual communication between partners, and
improve intimacy by reintroducing sexual
activity in a gradual way. Exercises begin with
nongenital touching and with successful
achievement of each progressive series of
exercises move to genital touching and, ultimately, penetrative sexual activity/intercourse
or other genital sexual activity. Sensate focus
may be more helpful in a subgroup of women
with HSDD secondary to penetration-related
anxiety and associated behavioral avoidance.
Cognitive Behavior Therapy. Cognitive
behavior therapy (CBT) focuses on altering
thoughts and behaviors that distract or result
in inhibiting (or nonexciting) sexual thoughts
in a sexual situation with speciﬁc focus on
automatic thoughts and beliefs that may inhibit
sexual desire (cognitive component).62 The
behavioral component of therapy serves to
change sexual behavior by focusing on pleasure
and not on sexual form and planned sexual
activity and self-exploration instead of avoidance of sexual activity. An important part of the
CBT approach is education that may help the
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woman and her partner understand the physiology and psychology of sexual desire and
change the perception of what is desire and sex.
McCabe63 found a CBT program to be effective in 44.4% of women with sexual health concerns. Cognitive behavior therapy was most
likely to be effective in women with anorgasmia
and sexual arousal disorder and least likely to
be effective in women who experienced a lack
of sexual interest. A total of 54% of women
who underwent CBT still reported a lack of sexual interest after CBT. Trudel et al64 found that
74% of women with HSDD were considered to
be improved by the end of a CBT group intervention. A total of 64% remained improved at 1-year
follow-up after CBT. Neither study had an
adequate control group paradigm.65
Mindfulness. The goal of mindfulness-based
cognitive therapy is to encourage participants to
connect and engage with their sexuality by
learning and practicing a variety of mindfulness
exercises that attempt to improve awareness of the
here and now and acceptance and self-compassion.66 Therapy also includes an educational
component regarding female sexuality and sexual
function. Session content may include helping
women discover the ways in which sexual interest
and motivation are inﬂuenced by thoughts, feelings, behaviors, and relationships. Another goal is
to improve awareness and, thus, alter the effect of
sexual function on mood and self-esteem.
The paucity of clinical trials and lack of
adequate controls in the published studies
that evaluate the efﬁcacy of psychotherapeutic
treatments of HSDD makes it difﬁcult to draw
any useful conclusions at this time.63-66
Neuroendocrine/Neurochemical Aspects
Flibanserin. Flibanserin, dosed at 100 mg at
bedtime, is a nonhormonal, centrally acting,
postsynaptic serotonin 1A receptor agonist
and a serotonin 2A receptor antagonist
(a multifunctional serotonin agonist and antagonist) that results in a decrease in serotonin activity and an increase in dopamine and
norepinephrine activity.67 Flibanserin is
currently the only FDA-approved treatment for
generalized acquired HSDD in premenopausal
women in the United States. A risk evaluation
and mitigation program requires certiﬁcation
of prescribing health care providers and pharmacists. Efﬁcacy may not emerge for several
Mayo Clin Proc. n January 2017;92(1):114-128
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weeks, and treatment should be discontinued
after 8 weeks if no beneﬁt is realized.68 Given
the limited clinical experience with ﬂibanserin
due to its recent approval, additional information is provided herein.
Statistically signiﬁcant efﬁcacy was established in 3 North American pivotal clinical
trials in premenopausal women with HSDD,
with daily dosing of ﬂibanserin 100 mg at
bedtime demonstrating increased sexual
desire, decreased sexually related distress,
and increased satisfying sexual events.68,69
The clinically meaningful beneﬁt of this therapy was established based on the patient
global impression of improvement, which
demonstrated self-reported responder rates
for sexual desire (minimally, much, or very
much improved) of 54% to 58% in premenopausal women for ﬂibanserin vs 40% to 48%
for placebo treatment. Similar efﬁcacy and
safety results were seen in studies of ﬂibanserin in postmenopausal women,70 but ﬂibanserin is not yet approved in this population.
Safety was also established in clinical trials
where the most common adverse events (AEs)
in terms of placebo-corrected rates of occurrence in premenopausal women were dizziness (9.2%), somnolence (8.3%), nausea
(6.5%), and fatigue (3.7%). Note that these
types of AEs are not uncommon with central
nervous systemeactive medications that inﬂuence serotonin. Most AEs were transient or
episodic, were mild to moderate in severity,
and were mitigated by bedtime dosing. The
discontinuation rate due to AEs was 13% in
patients treated with ﬂibanserin 100 mg and
6% in patients treated with placebo.68-71 A
dedicated driving study found that ﬂibanserin
use did not have a negative effect on next-day
cognitive function or driving performance.68
These results are reassuring regarding the
sedating effects of ﬂibanserin.
An alcohol interaction study, in which
excessive exposure to alcohol was observed
to add to the adverse effects of ﬂibanserin
when given in the morning, found increased
frequency and severity of sedation, hypotension, and syncope, which resolved in all cases
with lying down/Trendelenburg position.71 As
a result of this study, ﬂibanserin has a boxed
warning highlighting the increased risks of
“serious hypotension and syncope” with
concomitant use of alcohol.
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In the clinical trials leading to approval,
alcohol intake was not restricted, and 58% of
women (n ¼ 898) treated with ﬂibanserin
100 mg reported “social drinking” at study
entry. Although alcohol consumption was
not monitored during the trials, rates of
syncope and presyncope (including hypotension) remained low in the ﬂibanserin group
(0.8% in drinkers and 0.2% in nondrinkers)
vs the placebo group (0.3% in drinkers and
0.2% in nondrinkers).71 In comparison, hypotension and syncope are reported to have an
annual incidence of 6% in the general population and to account for 1% to 3% of emergency department visits and hospitalizations.72
Testosterone. Testosterone therapy is an
evidence-based off-label treatment for perimenopausal and postmenopausal women with
HSDD.73-79 Transdermal testosterone therapy
using the 300-mg/d patch has been consistently reported in multiple studies to be
effective for the treatment of HSDD. In
double-blind, placebo-controlled clinical trials
in naturally and surgically menopausal
women, testosterone therapy resulted in
statistically signiﬁcant improvements in the
number of satisfying sexual events, sexual
desire, and sexual distress that were 2-fold
greater than placebo.44,79 The short-term
safety of testosterone has been reported
across studies, and the most common AEs
include hirsutism and acne, which occur at
placebo-corrected rates of 3% to 8% in treated
women, although some studies in surgically
menopausal women have reported essentially
no difference between testosterone and
placebo treatment groups regarding AEs.79
Long-term safety of testosterone therapy
regarding breast cancer and cardiovascular
outcomes are limited to observational
studies.80-82 Women prescribed off-label
testosterone for HSDD should be carefully
monitored. Efﬁcacy may not emerge for
several weeks, and treatment should not be
continued beyond 6 months if no beneﬁt is
realized.83 Ideally, formulations should be
developed speciﬁcally for women.
Bupropion. Bupropion, a norepinephrinedopamine reuptake inhibitor, is approved as
an antidepressant and a treatment for smoking
cessation, but it is used as an off-label
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Bupropion
treatment
for
HSDD.84-86
sustained-release 150- to 400-mg daily dosing
has been investigated in several clinical trials
for the treatment of HSDD, improving sexual
function as measured by the Changes in Sexual
Functioning Questionnaire and the Brief Index
of Sexual Functioning for Women.85,86
Although safety data for bupropion is not
speciﬁcally available in women diagnosed as
having HSDD, the most common AEs in terms
of placebo-corrected rates of occurrence in
placebo-controlled clinical trials for depression
were tremor (13.5%), agitation (9.7%), dry
mouth (9.2%), constipation (8.7%), excessive
sweating (7.7%), dizziness (6.1%), and
nausea/vomiting (4%). The AEs caused discontinuation of treatment in approximately 10% of
2400 patients and volunteers in clinical trials.87
Buspirone. Buspirone, a serotonin 1A partial
agonist, is approved as an anxiolytic for
the management of generalized anxiety disorder
or the short-term relief of symptoms of anxiety,
and it is used as an off-label treatment
for HSDD.88-90 When buspirone was coadministered with selective serotonin reuptake
inhibitors for the treatment of depression, a
reduction in selective serotonin reuptake inhibitoreinduced sexual dysfunction was noted.
Fifty-eight percent of individuals treated with
buspirone reported an improvement in sexual
function compared with 30% treated with placebo.89 Studies of treatment of HSDD have not
been published.
Similar to bupropion, safety data for buspirone is not speciﬁcally available in women
diagnosed as having HSDD. The most common AEs in terms of placebo-corrected rates
of occurrence in placebo-controlled clinical
trials were dizziness (9%), nervousness (4%),
nausea (3%), and headache (3%). Approximately 10% of 2200 anxious patients in trials
discontinued treatment due to an AE.
Future
This ISSWSH expert consensus panel
reviewed current evidence related to multiple
facets of the most common female sexual
dysfunction, HSDD, including epidemiology,
physiology, pathophysiology, diagnosis, and
treatment. The aim was to review the stateof-the-art, clinically relevant information that
would be used by the health care provider to
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facilitate a broader understanding of the
condition of HSDD in affected women who
present during routine ofﬁce visits. In the
future, ISSWSH plans to develop a focused
consensus document exclusively concerning
a ﬁrst-ever step care, diagnostic, and treatment
paradigm for the management of women with
HSDD by the primary care physician. Also
note that other medical therapies for HSDD
are in development. Among these, bremelanotide, a centrally acting synthetic melanocortin
peptide, has demonstrated clinical efﬁcacy in
phase 2 studies.90

CONCLUSION
Hypoactive sexual desire disorder in women is
an important female sexual dysfunction that
has been well-characterized for more than 3
decades. Based on contemporary research, the
pathogenesis of HSDD is attributed to an imbalance in central sexual excitatory (dopamine,
norepinephrine, melanocortin, and oxytocin)
and sexual inhibitory (serotonin, opioid, endocannabinoid, and prolactin) pathways. Epidemiologic studies have identiﬁed multiple
contributing factors, such as psychological conditions, relationship concerns, medical conditions, medications, and menopause.
The health care provider should be aware
that diagnostic assessment of a woman with
HSDD engages a biopsychosocial perspective
and is primarily based on history. The
Decreased Sexual Desire Screener is a validated
instrument that aids in HSDD diagnosis. The
treatment of HSDD may also engage both
psychosocial and biological strategies. Treatment should focus on the factors that are
most distressing to the individual. Brief
ofﬁce-based counseling or referral for sex therapy may be helpful. Bupropion or buspirone
may be used as off-label treatments for
HSDD. Menopausal women with HSDD may
beneﬁt from off-label testosterone therapy.
Flibanserin is currently the only FDAapproved medication for the treatment of
premenopausal women with HSDD, having
been found to have clinically meaningful
beneﬁt in multiple randomized, doubleblind, placebo-controlled trials involving
thousands of participants. In conclusion,
HSDD is a highly prevalent but often undiagnosed condition that can effectively be
Mayo Clin Proc. n January 2017;92(1):114-128
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managed by the nonspecialist with appropriate
assessment and individualized treatment.
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